✉news HealthMedicine first seen 1 h ago, last 15 min ago, peak #27
Anitocabtagene autoleucel shows sustained response in multiple myeloma
Original: Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma
Anitocabtagene autoleucel, a cell therapy, is associated with sustained clinical responses in patients with heavily pretreated multiple myeloma, according to a report in medical news. The finding is notable for a disease where patients who have exhausted standard lines of treatment typically face poor outcomes. Clinicians are watching whether such CAR-T approaches can extend durable remissions.
Why now: New evidence on a cell therapy offering durable benefit to patients with limited treatment options is drawing medical attention.
Anitocabtagene autoleucelmultiple myeloma
Rank over time, top of the chart is #1. 2 snapshots from 1 h ago to 15 min ago.
Evidence
- Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma · 2 Minute Medicine
- Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma · 2 Minute Medicine
API: https://socialmediatrends-api.osmike.com/v1/trends/279522